About
Developing Longer-acting Versions of Existing Treatments
PROLOR Biotech, develops proprietary versions of therapeutic proteins and peptide drugs already approved for medical therapy, such as human growth hormone. The company's goal is to create longer-acting versions of existing therapies that could be administered, for example, by injection once a week rather than having to be administered daily. The company's three primary products are designed to treat growth hormone deficiency, hemophilia, and type 2 diabetes.
Identity
| Name | PROLOR Biotech |
|---|---|
| Slug | opko-biologics-f-k-a-prolor-biotech |
| Type / kind | startup |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgL6sq4oIDA |
Status
| Status | inactive |
|---|---|
| Status reason | Acquired (Inactive) by OPKO Health on Aug 2013 - closed due to acquisition |
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | Center District |
| HQ city | Ness Ziona |
| HQ address | Golda Me'ir St 7, Ness Ziyyona, Israel |
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsCells
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business models
B2B
Tags
proteinstherapeuticsbiopharmaceuticalobesitybiotechnology
Funding
| Total raised | — |
|---|---|
| Current stage | Acquired |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}